Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 4/20 | 0.38 |
| ▸ | CLK2 | P49760 | 4/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19082962 | 0.87 | CLK2 (0.39) | NPY5RLMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL17017079 | 0.80 | NPY5R (0.48) | NPY5RLMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL29829334 | 0.80 | NPY5R (0.48) | NPY5RLMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL19082961 | 0.80 | SMN1; SMN2 (0.54) | LMNAHTTSMN1; SMN2MAPK1RAB9A | |
| SCHEMBL22224341 | 0.77 | NPY5R (0.48) | NPY5RLMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL19082949 | 0.77 | KDR (0.34) | NPY5RLMNAHTTSMN1; SMN2NPC1 | |
| Rolodine SCHEMBL121916 | 0.76 | NPY5R (0.49) | NPY5RLMNASMN1; SMN2MAPK1DYRK1B | |
| SCHEMBL22224139 | 0.76 | NPY5R (0.52) | NPY5RLMNAHTTSMN1; SMN2MAPK1 | |
| SCHEMBL19082969 | 0.73 | CLK2 (0.40) | LMNAHTTCLK1CLK2CLK4 | |
| SCHEMBL19082956 | 0.72 | CYP1A2 (0.47) | LMNAHTTSMN1; SMN2MAPK1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, MT-ND2 | NPY5R 2204/4885LMNA 1132/4885HTT 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.